Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.

ABSTRACT:

Background and objectives

Dipeptidyl peptidase-4 (DPP4) inhibition is a potential strategy to increase the engraftment rate of haematopoietic stem/progenitor cells. A recent clinical trial using sitagliptin, a DPP4 inhibitor approved for type 2 diabetes mellitus, has been shown to be a promising approach in adults with haematological malignancies after umbilical cord blood (UCB) haematopoietic cell transplantation (HCT). On the basis of data from this clinical trial, a semi-mechanistic model was developed to simultaneously describe DPP4 activity after multiple doses of sitagliptin in subjects with haematological malignancies after a single-unit UCB HCT.

Methods

The clinical study included 24 patients who received myeloablative conditioning followed by oral sitagliptin with s

SUBMITTER: Velez de Mendizabal N 

PROVIDER: S-EPMC4133124 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature